Drug intelligence / Profile preview

aplitabart + FOLFIRI + bevacizumab

Development stage: Unknown
Lead developer: IGM Biosciences
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Intravenous

Overview

This drug regimen is a combination therapy that includes **aplitabart** (a monoclonal antibody under investigation for cancer), **FOLFIRI** (a chemotherapy regimen consisting of folinic acid/leucovorin, fluorouracil, and irinotecan), and **bevacizumab** (a monoclonal antibody targeting vascular endothelial growth factor A). This triple combination is designed for enhanced anti-tumor effects, leveraging: - aplitabart for immune modulation (precise mechanism is under research), - FOLFIRI for cytotoxic activity primarily used in metastatic colorectal cancer, - bevacizumab for anti-angiogenesis by inhibiting VEGF-A. The combination is being studied for advanced solid tumors, particularly metastatic colorectal cancer.

Other names: leucovorin + fluorouracil + irinotecan + aplitabart + bevacizumab

Targets

TOP1 (DNA Topoisomerase I)TNFRSF10B (DR5)VEGFA (Vascular endothelial growth factor A)TS (Thymidylate synthase)

Beyond the preview

Go deeper on aplitabart + FOLFIRI + bevacizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aplitabart + FOLFIRI + bevacizumab.

Explore the full profile